ライフサイエンスコーパス: programmed death

1 athways, to prevent cell elimination through programmed death.

2 e checkpoint blockade (ICB), especially anti-programmed death 1 (anti-PD-1) and anti-programmed death

3 s, the molecular mechanism for regulation of programmed death 1 (PD-1) and its ligand (PD-L1) is part

4 munoinhibitory receptors on T cells, such as programmed death 1 (PD-1) and lymphocyte activation gene

5 We focused on Programmed Death 1 (PD-1) and T cell Ig- and mucin-domai

6 ly recognized consequence of the use of anti-programmed death 1 (PD-1) antibodies in the treatment of

7 lantation (post-allo-HCT) and the success of programmed death 1 (PD-1) blockade in classical Hodgkin

8 Blocking the programmed death 1 (PD-1) immune inhibitory pathway is o

9 a platinum-based doublet with or without the programmed death 1 (PD-1) inhibitor pembrolizumab recomm

10 Response to programmed death 1 (PD-1) inhibitors has been associated

11 nhibition of immune checkpoint proteins like programmed death 1 (PD-1) is a promising therapeutic app

12 Programmed death 1 (PD-1) is an immunologic checkpoint t

13 Blocking programmed death 1 (PD-1) may enhance the durability of

14 Expression of programmed death 1 (PD-1) on CD8 T cells promotes T cell

15 ell-surface glycoproteins that interact with programmed death 1 (PD-1) on T cells to attenuate inflam

16 al of immune checkpoint inhibitors targeting programmed death 1 (PD-1) or its ligand (PD-L1) and cyto

17 Preclinical studies suggest that programmed death 1 (PD-1) pathway is critical to inhibit

18 The programmed death 1 (PD-1) pathway limits immune response

19 ts who have received prior ICI targeting the programmed death 1 (PD-1) pathway remains unknown.

20 Immunotherapy with antibodies to programmed death 1 (PD-1) produces lower response rates

21 Programmed death 1 (PD-1) receptor and its ligand (PD-L1

22 esponsive to immune checkpoint blockade with programmed death 1 (PD-1) targeted agents, novel immunot

23 oximately 75% of objective responses to anti-programmed death 1 (PD-1) therapy in patients with melan

24 Interaction between PD-L1 and its receptor, programmed death 1 (PD-1), inhibits the function of acti

25 lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1), which dampen effector respons

26 sponse and outcome after treatment with anti-programmed death 1 (PD-1).

27 ession of the inhibitory checkpoint molecule programmed death 1 (PD-1).

28 henocopy the diabetes progression induced by programmed death 1 (PD-1)/PD-L1 blockade and identify a

29 itumour activity of antibodies targeting the programmed death 1 (PD-1): programmed death ligand 1 (PD

30 Programmed death 1 (PD1) has emerged as a major inhibito

31 infiltrating lymphocyte (TIL)-based or anti- programmed death 1 (PD1) immunotherapy.

32 Programmed death 1 (PD1) is a negative regulator of T ce

33 Here, we describe a CXCR5(-)CXCR3(+) programmed death 1 (PD1)(hi)CD4(+) helper T cell populat

34 atients treated with nivolumab received anti-programmed death 1 agents after randomly assigned therap

35 i-programmed death ligand 1 (PD-L1) and anti-programmed death 1 agents has expanded treatment options

36 also correlated with therapeutic efficacy of programmed death 1 and PD-L1 inhibitors.

37 onding to immune-checkpoint blockade by anti-programmed death 1 antibodies (anti-PD1).

38 The anti-programmed death 1 monoclonal antibody pembrolizumab has

39 , and granzyme B and decreased expression of programmed death 1 on these cells.

40 re previously treated with platinum and anti-programmed death 1 or anti-programmed death ligand 1 (PD

41 ld only partly be rescued by blockade of the programmed death 1 pathway.

42 T cells express high levels of the receptor programmed death 1 protein (PD-1), while those from dise

43 ere associated with marked expression of the programmed death 1 protein (PD-1).

44 5 study, we evaluated pembrolizumab, an anti-programmed death 1 receptor antibody, in this platinum-

45 e both populations expressing high levels of programmed death 1 receptor.

46 gher rates of ipilimumab and ipilimumab/anti-programmed death 1 use in the HDI arm versus ipi3 and ip

47 s shown to be dampened by IL-10 and eventual programmed death 1-mediated T cell exhaustion.

48 that binds to the T-cell immune check point programmed death 1.

49 umber of effective strategies, including the programmed death 1/PD ligand 1 (PD-1/PD-L1) axis, to eva

50 Immunotherapeutic approaches, particularly programmed death 1/programmed death ligand 1 (PD-1/PD-L1

51 f specific TCR Vbeta subtypes, the impact of programmed death -1 (PD-1), CTL-associated protein 4 (CT

52 use of immune checkpoint therapies targeting programmed death-1 (PD-1) and its ligand (PD-L1) continu

53 The interactions between programmed death-1 (PD-1) and its ligands hamper tumor-s

54 monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interaction

55 therapies with monoclonal antibodies against programmed death-1 (PD-1) and programmed death ligand-1

56 Progenitors lacking the inhibitory receptors programmed death-1 (PD-1) and T cell immunoreceptor with

57 rammed death ligand-1 (PD-L1) interacts with programmed death-1 (PD-1) and the immunostimulatory mole

58 Zap-70, along with an enhanced expression of Programmed Death-1 (PD-1) and the skin-homing CCL17.

59 Immune checkpoint blockade of programmed death-1 (PD-1) by monoclonal antibody drugs h

60 Blocking Programmed Death-1 (PD-1) can reinvigorate exhausted CD8

61 Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor an

62 Cancer cells can exploit the programmed death-1 (PD-1) immune checkpoint pathway to a

63 lls (MDSCs), regulatory T cells (Tregs), and programmed death-1 (PD-1) inhibitory molecule expression

64 Programmed death-1 (PD-1) inhibits T and B cell function

65 Expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) is used to se

66 Cancer cells exploit the expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) to subvert T-

67 e chromosomal region (9p24.1) containing the programmed death-1 (PD-1) ligands PD-L1 and PD-L2 are re

68 alterations leading to overexpression of the programmed death-1 (PD-1) ligands, suggesting a possible

69 cies of expression of the regulatory protein programmed death-1 (PD-1) on plasmablasts/plasma cells i

70 The roles of the programmed death-1 (PD-1) receptor on lymphocytes and it

71 -1 (PD-L1) concurrent with enrichment of the programmed death-1 (PD-1) receptor.

72 a humanized monoclonal antibody against the programmed death-1 (PD-1) receptor.

73 Plasmodium spp., exploit the interaction of programmed death-1 (PD-1) with PD-1-ligand-1 (PD-L1) to

74 Pretreatment levels of programmed death-1 (PD-1)+ peripheral blood T cells (PD-

75 g antitumor adaptive T cell immunity via the programmed death-1 (PD-1)-programmed death ligand-1 (PD-

76 The programmed death-1 (PD-1)/programmed death-ligand 1 (PD-

77 tory T cells and CD4(+) T-cell expression of programmed death-1 and cytotoxic T lymphocyte-associated

78 cantly (p <= 0.05) increased CD4+ lymphocyte programmed death-1 and monocyte programmed death-ligand-

79 sEPD of anti-programmed death-1 antibody showed more potent anti-tumo

80 Purpose The addition of nivolumab (anti-programmed death-1 antibody) to ipilimumab (anti-cytotox

81 udy, we evaluated the efficacy and safety of programmed death-1 blockade by nivolumab in patients wit

82 Immunotherapy using programmed death-1 blockers is a promising modality for

83 The efficacy and safety of nivolumab (a programmed death-1 checkpoint inhibitor), alone or combi

84 Tumor cells can exploit the programmed death-1 checkpoint pathway to evade immune su

85 eath ligand 1 that, through interaction with programmed death-1 expressed on DCs, limited DC activati

86 stance was observed in the context of T-cell programmed death-1 expression and defects in interferon

87 Programmed death-1 homolog (PD-1H), a CD28/B7 family mol

88 Nivolumab, a fully human immunoglobulin G4 programmed death-1 immune checkpoint inhibitor antibody,

89 Nivolumab, an anti-programmed death-1 immune checkpoint inhibitor, and bren

90 with recurrent multifocal GBM with the anti-programmed death-1 inhibitor nivolumab, which resulted i

91 a (R/R HL), immunotherapies such as the anti-programmed death-1 inhibitor pembrolizumab have demonstr

92 Purpose Nivolumab, a programmed death-1 inhibitor, prolonged overall survival

93 f therapy with glutaminase, dual TORC1/2, or programmed death-1 inhibitors.

94 Expression of PD-L1 and programmed death-1 is elevated in the salivary glands of

95 PMBL is characterized by high expression of programmed death-1 ligand and variable expression of CD3

96 Nivolumab, an anti-programmed death-1 monoclonal antibody, has demonstrated

97 interacts with the constitutively expressed programmed death-1 on the target T cells and stimulates

98 off-label therapeutic use of antibody to the programmed death-1 protein (anti-PD-1) and had experienc

99 ed on >= 1 prior chemotherapy regimen and/or programmed death-1 receptor/programmed death ligand-1 [P

100 his is the largest analysis of data for anti-programmed death-1 therapy in mucosal melanoma to date.

101 cell coinhibitory receptors CTLA-4 and PD-1 (programmed death-1) that have shown activity in several

102 f IFN-gamma and IL-7R, reduced expression of programmed death-1, and decreased apoptosis.

103 Programmed death-1, CTLA4, and TIM-3 displayed discrete

104 Programmed death-1-directed (PD-1-directed) immune check

105 Here, we investigated whether programmed death-1-mediated (PD-1-mediated) T cell exhau

106 ase 2 phosphatase to the cytoplasmic tail of programmed death-1.

107 T cells, as well as immune checkpoints like programmed death-1.

108 onses by engaging the co-inhibitory receptor programmed death-1.

109 The immune checkpoint signal axis programmed death-1/programmed death-ligand 1 (PD-1/PD-L1

110 Programmed death and shedding of epithelial cells is a p

111 n increase in IL-10 and higher expression of programmed death ligand (PD-L)1 and PD-L2 - which were p

112 Costimulatory molecules, such as the programmed death ligand (PD-L1), might exert differentia

113 platinum and anti-programmed death 1 or anti-programmed death ligand 1 (PD-1/L1) therapy.

114 dies against programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) and cytotoxic T l

115 approaches, particularly programmed death 1/programmed death ligand 1 (PD-1/PD-L1) blockade, have im

116 Programmed cell death protein 1:programmed death ligand 1 (PD-1:PD-L1) and cytotoxic T l

117 The approval of anti-programmed death ligand 1 (PD-L1) and anti-programmed de

118 tumor endothelium to upregulate cell-surface programmed death ligand 1 (PD-L1) and galectin-9.

119 These cells also express programmed death ligand 1 (PD-L1) and interleukin-10, an

120 Blocking the interaction between Programmed Death Ligand 1 (PD-L1) and its receptor, PD-1

121 Programmed death ligand 1 (PD-L1) and PD-L2 are ligands

122 ll lymphomas (DLBCLs) express high levels of programmed death ligand 1 (PD-L1) and PD-L2.

123 For patients with high programmed death ligand 1 (PD-L1) expression (tumor prop

124 ed patients and in subgroups on the basis of programmed death ligand 1 (PD-L1) expression and human p

125 We assessed the association of efficacy with programmed death ligand 1 (PD-L1) expression and tumor m

126 1 (PD-1) inhibitors has been associated with programmed death ligand 1 (PD-L1) expression levels in s

127 Here we show that programmed death ligand 1 (PD-L1) expression on tumor ce

128 Positive tumor programmed death ligand 1 (PD-L1) expression was defined

129 eg, EGFR/ALK /ROS1), if the patient has high programmed death ligand 1 (PD-L1) expression, pembrolizu

130 py amplifies type I IFN signaling, increases programmed death ligand 1 (PD-L1) expression, tumor CD8(

131 ies targeting the programmed death 1 (PD-1): programmed death ligand 1 (PD-L1) immune checkpoint in l

132 similar cases strengthens the association of programmed death ligand 1 (PD-L1) inhibition with this r

133 omparing programmed cell death protein 1 and programmed death ligand 1 (PD-L1) inhibitors to docetaxe

134 Programmed death ligand 1 (PD-L1) is an immune checkpoin

135 Programmed death ligand 1 (PD-L1) is an immune regulator

136 Programmed death ligand 1 (PD-L1) is expressed on a numb

137 ibodies blocking programmed death receptor 1/programmed death ligand 1 (PD-L1) signaling have radical

138 Randomization was stratified according to programmed death ligand 1 (PD-L1) status, BRAF mutation

139 metastatic non-small-cell lung cancer with a programmed death ligand 1 (PD-L1) tumour proportion scor

140 immune resistance via CD4(+) T-cell loss and programmed death ligand 1 (PD-L1) upregulation challenge

141 kpoints program cell death protein 1 (PD-1), programmed death ligand 1 (PD-L1), and cytotoxic T lymph

142 onoclonal antibody that binds selectively to programmed death ligand 1 (PD-L1), in this patient popul

143 cond-line treatment option for patients with programmed death ligand 1 (PD-L1)-expressing advanced no

144 nivolumab with chemotherapy in patients with programmed death ligand 1 (PD-L1)-positive NSCLC.

145 1, as well as surface expression of CD86 and programmed death ligand 1 (PD-L1).

146 xpression of the immunosuppressive protein - programmed death ligand 1 (PD-L1).

147 ex vivo-matured and fetal liver HSCs express programmed death ligand 1 (PD-L1).

148 Recently, agents targeting the programmed death ligand 1 (PD-L1)/programmed death recep

149 Programmed death ligand 1 (PD-L1, also called B7-H1) is

150 nine-protein kinase B-Raf inhibitor and anti-programmed death ligand 1 antibody elicited higher local

151 gher pretreatment tumor CD8 cell density and programmed death ligand 1 expression, whereas all nonres

152 led robust T cell infiltration and prominent programmed death ligand 1 expression.

153 in the tumour microenvironment and increased programmed death ligand 1 expression.

154 Inactivation of either programmed death ligand 1 or IFNGR1 elicited a robust an

155 We further find that upregulation of the programmed death ligand 1 protein-a key checkpoint molec

156 Finally, programed death protein 1/programmed death ligand 1 signaling pathways were essent

157 ulated expression of the inhibitory molecule programmed death ligand 1 that, through interaction with

158 PD-L1 (programmed death ligand 1) and PD-L2 are cell-surface gl

159 immune-related genes involved in PD-1-PD-L1 (programmed death ligand 1) and T cell cytotoxicity pathw

160 (anti-cytotoxic T-lymphocyte antigen 4, anti-programmed death ligand 1) or proinflammatory cytokines

161 tations and expression of the protein PD-L1 (programmed death ligand 1).

162 Conclusion In patients with programmed death ligand 1-positive advanced cervical can

163 e safety and efficacy of pembrolizumab in 20 programmed death ligand 1-positive, advanced solid tumor

164 erate functional FOXP3(+) Treg cells through programmed death ligand 1.

165 markers human leukocyte antigen class II and programmed death ligand 1.

166 mors were analyzed for T-cell infiltrate and programmed death ligand 1.

167 mmunosuppressive microenvironment, including programmed death ligand 1/2 and chemokine (C-C motif) li

168 OF B cells had increased expression of CD48, programmed death ligand 1/2, and CD70.

169 ammed cell death 1 (PD-1) blockade induced a programmed death ligand 1/NOD-, LRR-, and pyrin domain-c

170 L (inducible costimulator ligand) and PD-L2 (programmed death ligand 2).

171 ored by antibody-mediated disruption of PD-1/programmed death ligand interaction.

172 CD8(+) T cells, with elevated expression of programmed death ligand-1 (PD-1) and lymphocyte activati

173 Programmed death ligand-1 (PD-L1) and cluster of differe

174 Extracellular interaction between programmed death ligand-1 (PD-L1) and programmed cell de

175 kinetics of antibody therapeutics targeting programmed death ligand-1 (PD-L1) can be quantified noni

176 Programmed cell death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) checkpoint blockade ha

177 ed low expression of the coinhibitory ligand programmed death ligand-1 (PD-L1) concurrent with enrich

178 ggest that IFN-gamma is a critical driver of programmed death ligand-1 (PD-L1) expression in cancer a

179 bodies against programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have shown little effi

180 or programmed cell death protein-1 (PD-1) to programmed death ligand-1 (PD-L1) have shown marked effi

181 Aberrant expression of programmed death ligand-1 (PD-L1) in tumor cells promote

182 Programmed death ligand-1 (PD-L1) interaction with PD-1

183 Programmed death ligand-1 (PD-L1) interacts with program

184 Programmed death ligand-1 (PD-L1) is a critical regulato

185 l immunity via the programmed death-1 (PD-1)-programmed death ligand-1 (PD-L1) pathway.

186 ive phenotype and increase the expression of programmed death ligand-1 (PD-L1) when treated with reac

187 macrophage population exhibiting the markers programmed death ligand-1 (PD-L1), Mac-2, and macrophage

188 One such major mechanism is the induction of programmed death ligand-1 (PD-L1), which mitigates adapt

189 ulatory and Th cells, total macrophages, and programmed death ligand-1 (PD-L1)-positive immune-suppre

190 y regimen and/or programmed death-1 receptor/programmed death ligand-1 [PD-(L)1] inhibitor, including

191 Programmed cell death-1 (PD-1)/programmed death ligand-1 blockade may potentially augme

192 Responses were achieved regardless of tumor programmed death ligand-1 expression.

193 overall survival (OS) and response by tumor programmed death ligand-1 expression.

194 toward improved PFS and OS in patients with programmed death ligand-1-positive tumors.

195 -CTLA4 mAb therapy but not with anti-PD-1 or programmed death ligand-1.

196 Checkpoint blockade therapy targeting the programmed-death ligand 1 (PD-L1) and its receptor progr

197 e identified the constituent proteins of the programmed-death ligand 1 (PD-L1) microenvironment in li

198 on in tumor microcirculation and mapping out programmed-death ligand 1 and programmed cell death prot

199 HCII) and promoting the tolerogenic markers, programmed death-ligand (PD-L)1, PD-L2, and the tryptoph

200 anti-programmed death 1 (anti-PD-1) and anti-programmed death-ligand 1 (anti-PD-L1) therapy, has beco

201 ne checkpoint signal axis programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) can effectively r

202 To investigate the expression of programmed death-ligand 1 (PD-L1) and immune checkpoints

203 s led to adaptive resistance by upregulating programmed death-ligand 1 (PD-L1) and resulted in tumor

204 emonstrate PVHA increased the uptake of anti-programmed death-ligand 1 (PD-L1) antibody in HA-accumul

205 ity of atezolizumab (MPDL3280A), a humanized programmed death-ligand 1 (PD-L1) antibody, in renal cel

206 which is enhanced when combined with an anti-programmed death-ligand 1 (PD-L1) antibody.

207 Durable tumor immunity required programmed death-ligand 1 (PD-L1) blockade in combinatio

208 Blockade of programmed death-ligand 1 (PD-L1) by therapeutic antibod

209 Programmed death-ligand 1 (PD-L1) down-modulates various

210 We evaluated the prognostic value of programmed death-ligand 1 (PD-L1) expression in CTCs in

211 It is now recognized that programmed death-ligand 1 (PD-L1) expression on cancer c

212 overcome the immune suppression mediated by programmed death-ligand 1 (PD-L1) expression on cancer c

213 Programmed death-ligand 1 (PD-L1) expression on malignan

214 mize noninvasive immuno-PET imaging of human programmed death-ligand 1 (PD-L1) expression, in a precl

215 mor activity of avelumab, a fully human anti-programmed death-ligand 1 (PD-L1) IgG1 antibody, in pati

216 at target the programmed cell death 1 (PD-1):programmed death-ligand 1 (PD-L1) immune checkpoint path

217 The programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunosuppressive path

218 emokine ligand 9 and 10 (CXCL9, CXCL10)) and programmed death-ligand 1 (PD-L1) in clinical TNBC speci

219 sis revealed a heterogeneous distribution of programmed death-ligand 1 (PD-L1) in Her2 transgenic mou

220 macrophages (TAMs) as the primary source of programmed death-ligand 1 (PD-L1) in human and murine CC

221 the role of Toll-like receptor 2 (TLR2) and programmed death-ligand 1 (PD-L1) in regulating alpha-(1

222 We hypothesize the programmed death-ligand 1 (PD-L1) inhibitor, durvalumab,

223 relies on combining gemcitabine and a novel programmed death-ligand 1 (PD-L1) inhibitor, termed MN-s

224 Programmed death-ligand 1 (PD-L1) is a key factor influe

225 Purpose Expression of programmed death-ligand 1 (PD-L1) is a potential predict

226 As we found that programmed death-ligand 1 (PD-L1) is highly expressed on

227 he potential of LXA4 treatment in regulating programmed death-ligand 1 (PD-L1) on KSHV-carrying tumor

228 e programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) pathway play an import

229 rexpression of the immune checkpoint protein programmed death-ligand 1 (PD-L1) protected HILO xenogra

230 Combining MEK inhibition with anti-programmed death-ligand 1 (PD-L1) resulted in synergisti

231 ity, biomarkers of response as determined by programmed death-ligand 1 (PD-L1) status, and on-therapy

232 n shows miRNA-mediated induced expression of Programmed Death-Ligand 1 (PD-L1) which inhibits T-cell

233 Inhibition of programmed death-ligand 1 (PD-L1) with atezolizumab can

234 ators programmed cell death protein 1 (PD1), programmed death-ligand 1 (PD-L1), and B and T lymphocyt

235 All GTT subtypes express programmed death-ligand 1 (PD-L1), and natural killer (N

236 c stellate cells (HSCs) suppress T cells via programmed death-ligand 1 (PD-L1), but it remains unknow

237 in the overall population and in those with programmed death-ligand 1 (PD-L1)-positive tumors.

238 metastatic renal cell carcinoma who express programmed death-ligand 1 (PD-L1).

239 immune-modulating proteins, one of which is programmed death-ligand 1 (PD-L1).

240 pressed on activated T cells and its ligand, programmed death-ligand 1 (PD-L1; encoded by the CD274 g

241 pletion following immune restoration by anti-programmed death-ligand 1 (PDL1) blockade.

242 This study assessed atezolizumab (anti-programmed death-ligand 1 [PD-L1]) as treatment for meta

243 he safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [PD-L1]) versus chemotherapy i

244 ted macrophages (TAMs) that expressed CD274 (programmed death-ligand 1 [PD-L1]), TGF-beta activation,

245 ) are increased, with elevated expression of programmed death-ligand 1 and IL-10, and decreased expre

246 Anti-programmed death-ligand 1 antibody (aPDL1), an immune ch

247 Tumor programmed death-ligand 1 expression and MSI-H/MMR-D sta

248 nts with higher-level Hodgkin Reed-Sternberg programmed death-ligand 1 expression had more favorable

249 ression, but exhibited impaired induction of programmed death-ligand 1 expression in a wide range of

250 ynergistic anticancer effect on reduction of programmed death-ligand 1 expression in LL/2 cells.

251 Programmed death-ligand 1 expression on tumor cells and

252 Chromosome 9p24.1 alterations and programmed death-ligand 1 expression were assessed in Ho

253 ents and Methods Patients were stratified by programmed death-ligand 1 expression, BRAF status, and b

254 sence of tumor-infiltrating T cells, but not programmed death-ligand 1 expression, in tumor tissue co

255 Efficacy was correlated with tumor programmed death-ligand 1 expression, microsatellite-hig

256 protein 4 or programmed cell death protein 1/programmed death-ligand 1 have displayed durable clinica

257 Focal induction of programmed death-ligand 1 in the tumor microenvironment,

258 In return, programmed death-ligand 1 interacts with the constitutiv

259 d, Ag administration induces upregulation of programmed death-ligand 1 on dendritic cells in a T cell

260 vels of MC2, but not those of CD80, CD86, or programmed death-ligand 1 or 2, correlated with T cell r

261 Tumor size and programmed death-ligand 1 status were among the baseline

262 activity against the programmed cell death-1/programmed death-ligand 1(PD-1/PD-L1) protein-protein in

263 eased expression of immune modulators PD-L1 (programmed death-ligand 1) and CD86 by myeloid DCs (mDCs

264 igh expression levels of the CD274 molecule (programmed death-ligand 1) and programmed cell death 1,

265 (cluster of differentiation 8), CD68, PD-L1 (programmed death-ligand 1), CD34, FAP (fibroblast activa

266 7) and the adaptive immune checkpoint PD-L1 (programmed death-ligand 1).

267 the regulatory pathways in T cells, such as programmed death-ligand 1, programmed cell death 1, or t

268 , epidermal growth factor receptor, CD71 and programmed death-ligand 1.

269 nced NF-kappaB activity, and upregulation of programmed death-ligand 1.

270 IgD and/or IgM expression (67%), and lack of programmed death-ligand 1/ligand 2.

271 Low programmed death-ligand 2 (PD-L2) was the most sensitive

272 l death protein-1 (PD-1) (-6.8 kcal/mol) and programmed death-ligand-1 (PD-L1) (-9.6 kcal/mol).

273 + lymphocyte programmed death-1 and monocyte programmed death-ligand-1 expression in most studies.

274 terations in translation of mRNAs, including programmed-death-ligand 1 (PD-L1).

275 ed suppressor cells (and their expression of programmed-death-ligand-1) in spinal cord-draining lymph

276 Programmed death ligands (PDLs) are immune-regulatory mo

277 S) and hypersensitive response (HR), a rapid programmed death of infected cells.

278 Programmed death one homolog (PD-1H) is an immunoglobuli

279 h p16 (Ad.E6E7p16) and also encoding an anti-programmed death (PD)-1 Ab.

280 dies against checkpoint molecules, including programmed death (PD)-1, PD ligand (PD-L)1, and cytotoxi

281 immune checkpoint (IC) molecules, including programmed death (PD)-1, T cell Ig and mucin domain-cont

282 The programmed death protein (PD) 1-PD ligand 1/2 pathway an

283 The programmed death protein (PD-1) and its ligand (PD-L1) p

284 ve response rate (ORR) for single-agent anti-programmed death receptor 1 (anti-PD-1) therapy is modes

285 activity of pembrolizumab, a humanised anti-programmed death receptor 1 (PD-1) antibody, in patients

286 % vs 18.6%, P = .05), a higher proportion of programmed death receptor 1 (PD-1) expressing memory CD4

287 geting the programmed death ligand 1 (PD-L1)/programmed death receptor 1 (PD-1) immune checkpoint wer

288 lymphocyte-associated protein 4 (CTLA-4) and programmed death receptor 1 (PD-1) were ineffective in c

289 s has been made clinically in inhibiting the programmed death receptor 1 (PD-1)/PD-L1 interaction to

290 nts with HCV were characterized by increased programmed death receptor 1 expression and reduced ADCC

291 treatment restored ADCC ability and reduced programmed death receptor 1 expression.

292 The anti-programmed death receptor 1 inhibitor nivolumab previous

293 n of inducer of costimulation (ICOS) ligand, programmed death receptor 1-ligand 1 (PD1-L1), CxxxC che

294 Therapeutic checkpoint antibodies blocking programmed death receptor 1/programmed death ligand 1 (P

295 /86 (CD80/86) interact with their receptors, programmed death receptor-1 (PD-1) and cytotoxic T-lymph

296 nal antibody that blocks interaction between programmed death receptor-1 (PD-1) and its ligands (PD-L

297 fector phenotype and decreased expression of programmed death receptor-1 (PD-1), in addition to an el

298 mmune checkpoint blockade with antibodies to programmed death receptor-1 (PD-1).

299 nalized neoantigen vaccine was combined with programmed death receptor-1 blockade in patients with ad

300 essor protein ARF sensitizes cancer cells to programmed death through a surprising mechanism: ARF phy